<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791799</url>
  </required_header>
  <id_info>
    <org_study_id>2022ZSLYEC-461</org_study_id>
    <nct_id>NCT05791799</nct_id>
  </id_info>
  <brief_title>Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicenter Prospective Randomized Controlled Clinical Study of Etonogestrel Implants to Protect Ovarian Reserve Function in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to test in female patients with systemic lupus erythematosus (SLE).&#xD;
      The main question it seeks to answer is whether etonogestrel implants can protect ovarian&#xD;
      reserve function in patients with SLE. Participants will be randomly divided into a test&#xD;
      group and a control group. The test group will be implanted subcutaneously with etongestrel&#xD;
      for one year. Researchers won't intervene in the control group. After three months of&#xD;
      drug-eluting, researchers will compare measures of ovarian reserve function in the test and&#xD;
      control groups to see if etonogestrel implants can protect ovarian reserve function in&#xD;
      patients with SLE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Mullerian hormone (AMH) serum level</measure>
    <time_frame>one year and three months</time_frame>
    <description>The serum AMH levels of the two groups will be compared one year and three months after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of antral follicle</measure>
    <time_frame>one year and three months</time_frame>
    <description>The number of antral follicles will be recorded by transvaginal ultrasound and compared one year and three months after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle-stimulating hormone (FSH) serum level</measure>
    <time_frame>one year and three months</time_frame>
    <description>The serum FSH levels of the two groups will be compared one year and three months after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>luteinizing hormone (LH) serum level</measure>
    <time_frame>one year and three months</time_frame>
    <description>The serum LH levels of the two groups will be compared one year and three months after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol (E2) serum level</measure>
    <time_frame>one year and three months</time_frame>
    <description>The serum E2 levels of the two groups will be compared one year and three months after enrollment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Etonogestrel implants group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will be subjected to etonogestrel implant (68mg) insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group of women will not be intervened.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel</intervention_name>
    <description>Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year</description>
    <arm_group_label>Etonogestrel implants group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Systemic lupus erythematosus was confirmed&#xD;
&#xD;
          2. 18-37 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of sex chromosome abnormalities&#xD;
&#xD;
          2. History of abnormal thyroid function&#xD;
&#xD;
          3. History of abnormal adrenal function&#xD;
&#xD;
          4. History of pituitary disease&#xD;
&#xD;
          5. History of sexual hormone drug use in the past 3 months&#xD;
&#xD;
          6. History of ovarian tumors or invasive ovarian operations&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Have a birth plan in the next 1 year&#xD;
&#xD;
          9. Ovarian failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyan Liang</last_name>
    <phone>86 020-38250752</phone>
    <email>liangxy2@mail.sysu.edu.cn</email>
  </overall_contact>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 1, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

